<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04597229</url>
  </required_header>
  <id_info>
    <org_study_id>LLKuan</org_study_id>
    <nct_id>NCT04597229</nct_id>
  </id_info>
  <brief_title>Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus</brief_title>
  <official_title>Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus: A Randomized Human Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiti Sains Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiti Sains Malaysia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy of instant multigrain supplementation&#xD;
      on the glycemic status, cardiometabolic implications, oxidative stress and nutritional status&#xD;
      in Type II DM patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type II DM is a highly prevalent and heterogeneous condition. New treatment modalities to&#xD;
      complement existing interventions are therefore of great interest, including dietary&#xD;
      interventions for primary prevention or as a possible therapeutic option that may confer&#xD;
      beneÔ¨Åts beyond currently recommended conventional therapies. Hence, the present work aims to&#xD;
      evaluate the efficacy of instant multigrain supplementation on the glycemic status,&#xD;
      cardiometabolic implications, oxidative stress and nutritional status in Type II DM patients,&#xD;
      as compare to standardized medication regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Actual">June 14, 2021</completion_date>
  <primary_completion_date type="Actual">May 26, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Glycated haemoglobin (HbA1c)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Glycated hemoglobin (HbA1c) is measured in %</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of fasting plasma glucose (FPG)</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Glycated hemoglobin (HbA1c) is measured in mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of fasting serum insulin</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Fasting serum insulin will be measured by radioimmunoassay kit</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Type2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Instant multigrain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral instant multigrain supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care without oral instant multigrain supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Instant multigrain supplement</intervention_name>
    <description>A twice daily instant multigrain supplementation for 12 weeks</description>
    <arm_group_label>Instant multigrain</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria for the clinical trial are:&#xD;
&#xD;
          -  Clinical diagnosis with Type II DM for at least 6 months' duration without clinically&#xD;
             manifest complications (retinopathy, diabetic nephropathy, vascular diseases, foot&#xD;
             ulcer - as diagnosed by the physician/recorded in database)&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Pharmacological treatment with metformin or insulin, or a combination of metformin and&#xD;
             glibenclamide.&#xD;
&#xD;
          -  Chronological age: 18 years and above&#xD;
&#xD;
          -  Metabolically stable (current laboratory results for A1C 6.0-8.5%; or fasting plasma&#xD;
             glucose 6.4-8.5 mmol/l)&#xD;
&#xD;
          -  Not taking antioxidant/anti-inflammatory supplements (Example of antioxidant: vitamin&#xD;
             C, vitamin E, grape seed extract, garlic capsule, ginkgo biloba) (Example of&#xD;
             anti-inflammatory supplement: fish oil, curcumin extract, ginger extract, spirulina)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having liver (chronic liver failure, cirrhosis, all types of hepatitis), kidney&#xD;
             (chronic kidney disease, haemodialysis) or haematological (anaemia, thalassemia,&#xD;
             haemophilia) disorders&#xD;
&#xD;
          -  Active gastric/duodenal ulcer&#xD;
&#xD;
          -  Psychiatric disease/mental retardation (bipolar disorder, depression, schizophrenia)&#xD;
&#xD;
          -  Cancer (all types), and endocrine disorders (Cushing's disease, gigantism and&#xD;
             hyperthyroidism).&#xD;
&#xD;
          -  Alcohol and drug abuse (self-mentioned or as recorded in the medical card)&#xD;
&#xD;
          -  Gestational Diabetes Mellitus&#xD;
&#xD;
          -  Pregnancy/lactation&#xD;
&#xD;
          -  Hormone replacement therapy (for at least 3 months prior to entering the study)&#xD;
&#xD;
          -  Herbal remedies (any parts from the plants such as flowers, rhizome, seeds, roots,&#xD;
             leaves, fruits, stems)&#xD;
&#xD;
          -  Use of steroids, chemotherapy, immunosuppressant or radiotherapy.&#xD;
&#xD;
          -  Vegetarian patient (pure vegan)&#xD;
&#xD;
          -  Gluten intolerance&#xD;
&#xD;
          -  Participations currently under another supplementary program&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Advanced Medical and Dental Institute (AMDI)</name>
      <address>
        <city>Kepala Batas</city>
        <state>Pulau Pinang</state>
        <zip>13200</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2020</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiti Sains Malaysia</investigator_affiliation>
    <investigator_full_name>Dr. Lee Lai Kuan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

